Department of Neurology, Duke University Medical Center, 2301 Erwin Road, Durham, NC, 27710, USA.
Division of Cardiothoracic Surgery, Department of Surgery, Duke University Medical Center, Durham, USA.
Sci Rep. 2021 Jan 18;11(1):1645. doi: 10.1038/s41598-021-81445-8.
Stroke is a devastating complication of left ventricular assist device (LVAD) therapy. Understanding the characteristics, risk factors and outcomes of strokes associated with the centrifugal flow LVADs is important to devise better strategies for management and prevention. This is a retrospective cohort study at a single US academic medical center. The cohort includes patients who received a first time Heartmate 3 (HM3) or Heartware (HVAD) LVAD between September 2009 through February 2018 and had a stroke while the LVAD was in place. Descriptive statistics were used when appropriate. A logistic regression analysis was used to determine predictors of poor outcome. Out of a total of 247 patients, 12.1% (N = 30, 24 HVAD and 6 HM3) had a stroke (63% ischemic) and 3 of these patients had pump thrombosis. Events per patient year (EPPY) were similar for HVAD and HM3 patients (0.3 ± 0.1). INR was subtherapeutic in 47.4% of ischemic stroke patients and supratherapeutic in 18.2% of hemorrhagic stroke patients. Concurrent infections were more common in the setting of hemorrhagic stroke than ischemic stroke (45.4% vs 5.3%, p = 0.008). Strokes were severe in most cases, with initial NIH stroke scale (NIHSS) higher in HM3 patients compared to HVAD patients (mean 24.6 vs 16) and associated with high in-patient mortality (21.1% of ischemic stroke vs. 88.8% of hemorrhagic stroke). Predictors of death within 30 days and disability at 90 days included creatinine at stroke onset, concurrent infection, hemorrhaghic stroke, and initial stroke severity (NIHSS). A score derived from these variables predicted with 100% certainty mortality at 30 days and mRS ≥ 4 at 90 days. For patients with centrifugal flow LVADs, ischemic strokes were more common but hemorrhagic strokes were associated with higher in-patient mortality and more frequently seen in the setting of concurrent infections. Infections, sub or supratherapeutic INR range, and comorbid cardiovascular risk factors may all be contributing to the stroke burden. These findings may inform future strategies for stroke prevention in this population.
中风是左心室辅助装置(LVAD)治疗的一种严重并发症。了解与离心流 LVAD 相关的中风的特征、风险因素和结局对于制定更好的管理和预防策略非常重要。这是在美国一家学术医疗中心进行的回顾性队列研究。该队列包括 2009 年 9 月至 2018 年 2 月期间首次接受 Heartmate 3(HM3)或 Heartware(HVAD)LVAD 治疗且在 LVAD 植入期间发生中风的患者。当适当时使用描述性统计。使用逻辑回归分析确定不良结局的预测因素。在总共 247 名患者中,12.1%(N=30,24 例 HVAD 和 6 例 HM3)发生中风(63%为缺血性),其中 3 例患者发生泵血栓形成。HVAD 和 HM3 患者的每患者年事件数(EPPY)相似(0.3±0.1)。缺血性中风患者的 INR 低于治疗范围的占 47.4%,高于治疗范围的占 18.2%。出血性中风患者并发感染的情况比缺血性中风患者更常见(45.4%比 5.3%,p=0.008)。大多数情况下中风较为严重,HM3 患者的初始 NIH 中风量表(NIHSS)高于 HVAD 患者(平均 24.6 比 16),且与住院死亡率高相关(缺血性中风的 21.1%比出血性中风的 88.8%)。30 天内死亡和 90 天残疾的预测因素包括中风发作时的肌酐、并发感染、出血性中风和初始中风严重程度(NIHSS)。根据这些变量得出的评分可 100%准确预测 30 天内的死亡率和 90 天的 mRS≥4 率。对于使用离心流 LVAD 的患者,缺血性中风更为常见,但出血性中风与更高的住院死亡率相关,并且更常发生在并发感染的情况下。感染、INR 低于或高于治疗范围以及并存的心血管危险因素可能都与中风负担有关。这些发现可能为该人群的中风预防策略提供信息。